MEDFORD, NY and RIO DE JANEIRO, BRAZIL--(Marketwire - January 29, 2008) - Chembio Diagnostics, Inc. (OTCBB: CEMI) (“Chembio” or the “Company”) and the Bio-Manguinhos unit of the Oswaldo Cruz Foundation of Brazil today announced the completion of three new technology transfer, supply and license agreements for products being developed by Chembio with its patented Dual Path Platform (DPP™) technology. Previously, in 2004, Bio-Manguinhos and Chembio entered into a similar agreement concerning one of Chembio’s HIV rapid tests.
